Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation study ; volume:271 ; number:10 ; day:4 ; month:9 ; year:2024 ; pages:6956-6969 ; date:10.2024
Journal of neurology ; 271, Heft 10 (4.9.2024), 6956-6969, 10.2024
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-024-12665-x
- URN
-
urn:nbn:de:101:1-2412192150334.756951526378
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chalitsios, Christos V.
- Ley, Harriet
- Gao, Jiali
- Turner, Martin R.
- Thompson, Alexander G.
- SpringerLink (Online service)
Other Objects (12)
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Nicotinic acid: a lipid-lowering agent with unrealized potential
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Nicotinic acid: a lipid-lowering agent with unrealized potential
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Nicotinic acid: a lipid-lowering agent with unrealized potential
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications